News

Intellegens and Biorelate have AI tools, which can enhance e-Therapeutics’ existing computational network-driven drug discovery (NDD) technology. Intellegens is a spin-out from the University of Cambridge, which has developed an

Following this study the two companies have agreed the terms of a licensing deal which will allow them to develop drug conjugates using the combined technologies.  The detailed

Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to

The investment, which came in a Series A financing round, was co-led by new investors Google Ventures (GV) and Sequoia China alongside existing investor Oxford Sciences Innovation. Neptune

Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for

The partnership intends to develop a complete and final manufacturing process to enable CombiGene advance to commercial good manufacturing practices (GMP) production and subsequent clinical trials. CGT Catapult believes that

The subpoena broadly requests documents including, among others, those produced in past or pending lawsuits and those relating to product safety and efficacy, overdoses, diversion, thefts, overprescribing, abuse/misuse,

KWS BioTest specializes in in vitro and in vivo discovery testing services for immuno-oncology, inflammation and allergy, autoimmune disease and antimicrobials, antivirals, and vaccinology. The acquisition is expected to

BRUDAC’s panel voted six in favor and thirteen against the benefit/risk profile of the company’s oral testosterone product candidate for testosterone replacement therapy (TRT) in adult males for